17,261 trials
HIV Infections · Acquired Immunodeficiency Syndrome
Primary: Change From Baseline in Plasma Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) on Day 10 (Cohort I) — -1.93; -1.98; -1.66; -2.16 copies/mL
Kidney Failure, Chronic · Diabetic Nephropathies · Glomerulonephritis, IGA
Primary: The Number of Subjects Who Experience a Decrease in Their Panel of Reactive Antibodies (PRA) at 6 Months Post Rituximab Infusion. — 6 Participants
Nasopharyngeal Carcinoma
Primary: 3 Month Loco-regional Control After Cetuximab With Concurrent Chemoradiotherapy — 100 participants with loco-regional control
Meningococcal Infections · Meningococcal Meningitis
Primary: Number of Participants With At Least One Solicited Injection Site or Systemic Reaction Post-Vaccination 1. — 26; 20; 28; 23 Participants
Nasopharyngeal Neoplasms · Carcinoma
Primary: Number of Participants With Complete Response (CR) — 1; 0 participants — p=1.0000
Venous Stasis Ulcers
Primary: Safety and Tolerability of Thymosin Beta 4 (Tβ4) Applied to Patients With Venous Stasis (VS) Ulcers for up to 84 Days — 24; 104 SAEs and AEs
Rheumatoid Arthritis
Primary: American College of Rheumatology (ACR) 20 at Week 12 — 12 participants
Methamphetamine Dependence
Primary: Heart Rate — 79.66 beats per minute
Ovarian Cancer
Primary: Patients' Overall 90-Day Clinical Response as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) — 8; 18 Participants
Non-Small Cell Lung Cancer · Lung Cancer, Non-Small Cell
Primary: Number of Participants Achieving Tumor Shrinkage Based on Change in Tumor Volume — 2; 33 participants
Contraception
Primary: Pearl Index — 0.17; 0.82; 0.00 Number per 100 women years
Psoriasis
Primary: Psoriasis Area and Severity Index 75 (PASI75) Response at Week 10 — 16 participants
Coronary Arteriosclerosis · Acute Coronary Syndrome
Primary: Maximum Platelet Aggregation (MPA) to 20 Micromolar (uM) Adenosine Diphosphase (ADP) — 41.1; 55.0; 41.0 percent maximum platelet aggregation (%) — p=<0.0001
Sleep Disorders, Circadian Rhythm
Primary: Latency to Persistent Sleep Over a 2-night Average Measured by Polysomnography (Nights 6-7) — 59.30; 39.40; 55.94; 55.12 minutes — p=0.646
Mesothelioma
Primary: Best Overall Response by RECIST Criteria (Version 1.0) — 3; 0; 7; 6 eligible, treated participants